Tumor-targeting nanosystems for the delivery of siRNA

Nanomedicine

Volumn 2, Issue 4, 2007, Pages 569-572

  Aigner, Achim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

HER 2; In vivo; Nanoimmunoliposome; RNA interference; siRNA delivery

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 3; DOUBLE STRANDED RNA; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HISTIDINE; IMMUNOLIPOSOME; LIPOSOME; LYSINE; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NANOPARTICLE; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CHEMICAL MODIFICATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SPECIFICITY; DRUG TARGETING; ENDOSOME; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG METASTASIS; MONOTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 34548460304     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.2.4.569     Document Type: Article

References (12)

1. Pirollo KF, Rait A, Zhou Q et al.: Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67(7), 2938-2943 (2007).
2. Aigner A: Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol. DOI: 10.1007/s00253-007-0984-y (2007) (Epub ahead of print).
3. Xu L, Tang WH, Huang CC et al.: Systemic p53 gone therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med. 7(10), 723-734 (2001).
4. Xu L, Huang CC, Hung W et al.: Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1(5), 337-346 (2002).
5. Pirollo KF, Zon G, Rait A et al.: Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17(1), 117-124 (2006).
6. Yu W, Pirollo KF, Yu B et al.: Enhanced transfectinn efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res. 32(5), e48 (2004).
7. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12(5), 461-466 (2005).
8. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58(13), 2825-2831 (1998).
9. Heil F, Hemmi H, Hochrein H et al.: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
10. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457-462 (2005).
11. Sloud M: Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348(5), 1079-1090 (2005).
12. Behlke MA: Progress towards in vivo use of siRNAs. Mol. Ther. 13(4), 644-670 (2006).